Since synthetic agonists for PPARα and LXRα are reported to increase cholesterol efflux and ameliorate lipid-related glomerular disease [31], [32], [34], it can be speculated that these NHRs in mesangial cells represent therapeutic targets for treating glomerular injuries in DN. This evidence concerns the gene PPARA and glomerular disorder.